Quivive Pharma

Executive Summary

Quivive Pharma is a San Diego-based biopharmaceutical company dedicated to addressing the opioid crisis through innovative small molecule therapeutics. Founded in 2019, the company has developed a functional antagonist that selectively mitigates opioid-induced respiratory depression without affecting analgesic efficacy, a key differentiator from current treatments like naloxone. With an approved product, Quivive is positioned to capture a significant share of the opioid safety market, addressing a critical unmet need in pain management. The company's technology platform enables potential expansion into other indications where respiratory depression is a concern. Quivive's novel approach has garnered interest from healthcare providers and payers seeking safer opioid alternatives, and its approved status provides a clear path to revenue generation. The company remains focused on commercial execution and further clinical development to maximize the impact of its therapeutic.

Upcoming Catalysts (preview)

• Q3 2026Initiation of label expansion trials for pediatric use70% success
• Q4 2026Announcement of commercial partnership for distribution in Europe80% success
• Q1 2027Publication of real-world evidence demonstrating reduced mortality60% success